Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.

More severe alopecia areata can lower quality of life.

Upadacitinib improved multiple immune-related conditions in one patient.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Alopecia areata causes significant psychological distress in cancer patients, needing integrated care.

Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

CD27 and IL-35 can help diagnose alopecia areata linked to bacterial infections.

Understanding different types of hair loss helps in accurate diagnosis and treatment.

Higher air pollution increases the risk of alopecia areata.

Baricitinib effectively regrows hair in severe alopecia areata cases.

Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.

Bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata may share immune-related causes.

Tofacitinib can help regrow hair in about 50% of people with moderate-severe alopecia areata.

Dupilumab may cause hair loss, so patients should be monitored.

Microneedling can effectively promote hair regrowth in alopecia areata.

Body structure can help identify alopecia areata in Ukrainian men, but not predict its course.

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.

Over half of alopecia areata patients in Tunisia experience depression, highlighting the need for psychological support.

The SBN system effectively assesses alopecia areata severity and predicts its course.

Latanoprost is more effective than minoxidil for treating alopecia areata.

More research is needed to find the best long-term treatments for Alopecia Areata.